Weill Cornell Medicine Radiation Oncology
525 East 68th Street
Stich Radiation Center
New York, NY 10065
New and Existing Patients
Already a patient?
Login or sign-upto Connect Patient Portal to make an appointment
Locations and Appointments
New Patients
Insurances Accepted
Please contact the doctor's office to verify that your insurance is accepted.
1199 National Benefit Fund
AETNA
Aetna - NYP
Amida Care
Anthem Blue Cross Blue Shield
Anthem Blue Cross/Blue Shield
Anthem Blue Cross/Blue Shield Healthplus
CIGNA
EmblemHealth
Empire Blue Cross/Blue Shield
Fidelis Care
GHI
Health Insurance Plan of NY (HIP)
Healthfirst
Healthspring
Local 1199
Molina Healthcare
Multiplan
Oxford Health Plans
Quality Health Management (QHM)
Rockefeller University/Luminare
United Healthcare
UnitedHealthcare
VNS Health
VNSNY CHOICE
WellCare
WorldWide Medical
About Andrew Brandmaier, M.D., Ph.D.
Dr. Brandmaier is a Radiation Oncologist focusing primarily on patients with Breast cancer and Brain tumors. He is actively involved with research and clinical trials combining radiation and immunotherapy for cancer.
He obtained a Bachelor of Science in Chemistry from Duke University and completed the MD/PhD program at Indiana University School of Medicine. His Radiation Oncology residency was done at New York Presbyterian Hospital/Cornell.
Expertise
- Resident Education
Education
- Fellowship: National Cancer Institute
- Internship: St. Francis Hospital
- Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Languages
- English
Titles & Positions
- Assistant Attending Radiation Oncologist
- Assistant Professor of Radiation Oncology
Hospital Affiliations
- NewYork-Presbyterian / Weill Cornell Medical Center
- NewYork-Presbyterian Brooklyn Methodist Hospital
- NewYork-Presbyterian Queens Hospital
Education
- Fellowship: National Cancer Institute
- Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Internship: St. Francis Hospital
Titles & Positions
- Assistant Attending Radiation Oncologist
- Assistant Professor of Radiation Oncology
Languages Spoken
- english
Research
[68Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker.
September 02, 2026Clinical Utility of [18F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma.
June 03, 2026Long-term outcomes of active surveillance after DOTATATE PET/MRI-confirmed gross total resection in WHO grade 2 meningioma.
September 18, 2025